17 unknown. 17 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 17 | Unknown 17 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR） - Diffuse Large B-cell Lymphoma (DLBCL) | Not applicable | Unknown | Zhejiang Cancer Hospital | 30 | 2024-09-01 | 2025-02-18 |
| The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. Mitoxantrone hydrochloride liposome injection, RiTUXimab Injection, Cyclophosphamid - Diffuse Large B-cell Lymphoma | Not applicable | Unknown | The First Hospital of Jilin University | 20 | 2023-09-01 | 2023-08-18 |
| Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL Venetoclax, Carmustine, Cytarabine - Diffuse Large B Cell Lymphoma | Not applicable | Unknown | Ruijin Hospital | 52 | 2023-06-01 | 2023-05-18 |
| R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Rituximab, Mitoxantrone hydrochloride liposome, Isophosphamide - Diffuse Large B-cell Lymphoma | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2023-04-15 | 2023-03-27 |
| R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma Rituximab, Mitoxantrone hydrochloride liposome, Cyclophosphamide - Diffuse Large B-cell Lymphoma | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 30 | 2023-03-01 | 2023-03-21 |
| Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients Rituximab, Orelabrutinib, Pomalidomide - Diffuse Large B Cell Lymphoma | Not applicable | Unknown | The First Affiliated Hospital of Soochow University | 35 | 2023-01-04 | 2023-04-20 |
| Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL Autologous anti-CD19 CAR-T cell injection - Diffuse Large B Cell Lymphoma | Not applicable | Unknown | The Affiliated Hospital of Qingdao University | 10 | 2022-04-01 | 2022-03-08 |
| Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma Lenalidomide - Diffuse Large B Cell Lymphoma | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 124 | 2020-06-14 | 2020-06-16 |
| the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy broken Ganoderma lucidum spore powder, placebo - Diffuse Large B-cell Lymphoma | Not applicable | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 120 | 2020-06-06 | 2021-06-04 |
| 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma 18F-FDG PET SCAN, MRI DIFFUSION - Diffuse Large B Cell Lymphoma | Not applicable | Unknown | Centre Antoine Lacassagne | 74 | 2017-10-13 | 2023-11-13 |
| The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma PL-doxorubicin and epirubicin - Diffuse Large B-cell Lymphoma | Not applicable | Unknown | Hebei Medical University Fourth Hospital | 270 | 2016-11-01 | 2017-01-16 |
| 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma 18F-FDG PET/CT - Lymphoma, Large B-Cell, Diffuse | Not applicable | Unknown | Peking University Cancer Hospital & Institute | 100 | 2016-10-01 | 2016-10-10 |
| Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma 18F-FDG PET/CT - Lymphoma, Large B-Cell, Diffuse | Not applicable | Unknown | Peking University Cancer Hospital & Institute | 100 | 2016-10-01 | 2016-10-12 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 anti-CD19-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Unknown | Chinese PLA General Hospital | 12 | 2013-04-01 | 2016-01-28 |
| Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients Early interim FDG PET/CT after 1 cycle of R-CHOP - Lymphoma, Large B-Cell, Diffuse | Not applicable | Unknown | The Catholic University of Korea | 53 | 2012-03-02 | 2022-08-05 |
| Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma bleomycin sulfate, filgrastim, rituximab - Lymphoma | Not applicable | Unknown | University Hospital Southampton NHS Foundation Trust | 120 | 2007-06-01 | 2009-07-08 |
| Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy - Chronic Myeloproliferative Disorders, Kidney Cancer | Not applicable | Unknown | University of California, San Francisco | 35 | 2005-05-01 | 2014-01-06 |
Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Prolymphocytic (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Blast Crisis (1) · Carcinoma, Renal Cell (1) · Congenital Abnormalities (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Kidney Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Accelerated Phase (1)
Hemic and Lymphatic Diseases (17) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Lymphatic Diseases (17) · Lymphoma, B-Cell (17) · Lymphoma, Non-Hodgkin (17) · Lymphoproliferative Disorders (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Lymphoma (14) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Leukemia, B-Cell (2) · Leukemia, Lymphoid (2)
Rituximab (8) · Cyclophosphamide (5) · Vincristine (4) · Prednisone (3) · Cytarabine (2) · Etoposide (2) · Filgrastim (2) · Ifosfamide (2) · Methotrexate (2) · Prednisolone (2) · Vindesine (2) · Antilymphocyte Serum (1) · Bleomycin (1) · Busulfan (1) · Carmustine (1)
The First Affiliated Hospital with Nanjing Medical University (3) · Peking University Cancer Hospital & Institute (2) · Centre Antoine Lacassagne (1) · Chinese PLA General Hospital (1) · Hebei Medical University Fourth Hospital (1) · Ruijin Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · The Affiliated Hospital of Qingdao University (1) · The Catholic University of Korea (1) · The First Affiliated Hospital of Soochow University (1) · The First Hospital of Jilin University (1) · University Hospital Southampton NHS Foundation Trust (1) · University of California, San Francisco (1) · Zhejiang Cancer Hospital (1)
China (9) · France (1) · South Korea (1) · United Kingdom (1) · United States (1)
Wei Xu, PhD& MD (2) · Xuejuan Wang, MD (2) · Charles A. Linker, MD (1) · Haiyan Yang, PhD (1) · Joo Hyun O, MD (1) · Liu Lihong, archiater (1) · Peter Johnson, MD (1) · Seok-Goo Cho, MD, PhD (1) · Wei Xu, M.D., Ph.D (1)
PMID 26451310, PMID 29599530, PMID 35530320, PMID 37114393, PMID 42426809